Improvement of the trivalent inactivated flu vaccine using papmv nanoparticles

52Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.

Abstract

Commercial seasonal flu vaccines induce production of antibodies directed mostly towards hemaglutinin (HA). Because HA changes rapidly in the circulating virus, the protection remains partial. Several conserved viral proteins, e.g., nucleocapsid (NP) and matrix proteins (M1), are present in the vaccine, but are not immunogenic. To improve the protection provided by these vaccines, we used nanoparticles made of the coat protein of a plant virus (papaya mosaic virus; PapMV) as an adjuvant. Immunization of mice and ferrets with the adjuvanted formulation increased the magnitude and breadth of the humoral response to NP and to highly conserved regions of HA. They also triggered a cellular mediated immune response to NP and M1, and long-lasting protection in animals challenged with a heterosubtypic influenza strain (WSN/33). Thus, seasonal flu vaccine adjuvanted with PapMV nanoparticles can induce universal protection to influenza, which is a major advancement when facing a pandemic. © 2011 Savard et al.

Cite

CITATION STYLE

APA

Savard, C., Guérin, A., Drouin, K., Bolduc, M., Laliberté-Gagné, M. E., Dumas, M. C., … Leclerc, D. (2011). Improvement of the trivalent inactivated flu vaccine using papmv nanoparticles. PLoS ONE, 6(6). https://doi.org/10.1371/journal.pone.0021522

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free